新近的研究表明,干扰素α-2b合用利巴韦林治疗慢性丙肝,与单用干扰素α-2b治疗相比,可使更多的患者HCV RNA持续阴性,但费用要贵2～3倍。此研究旨在评价单用干扰素α-2b或合用利巴韦林对不同基因型HCV慢性肝炎患者的长期效果、费用和边际费用-效果。研究者在瑞典1744例慢性丙肝初治患者随机、双盲、安慰剂对照研究资料的基础上,比较不同治疗方案的费用-效果比。该模式由11种疾病状态组成:病毒阴性、轻度肝炎、中度肝炎、硬化性肝炎、利尿剂敏感性腹水、难治性腹水、曲张静 Recent studies have shown that interferon α-2b in combination with ribavirin in the treatment of chronic hepatitis C can persistently negative for HCV RNA in more patients than interferon α-2b alone, but at a cost of 2 to 3 times more expensive . This study was designed to evaluate the long-term efficacy, cost, and marginal cost-effectiveness of interferon alpha-2b alone or in combination with ribavirin for patients with HCV genotypes of HCV chronic hepatitis. Based on a randomized, double-blind, placebo-controlled study of 1744 newly diagnosed chronic hepatitis C patients in Sweden, the researchers compared the cost-benefit ratio of different treatment regimens. The pattern consists of 11 disease states: viral-negative, mild hepatitis, moderate hepatitis, cirrhosis, diuretic-sensitive ascites, refractory ascites, Qu Zhangjing